Business Wire

  1. Felycin-CA1 (Sirolimus Delayed-Release Tablets) Is The First And Only Drug FDA Approved For The Management Of Ventricular Hypertrophy In Cats With Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting As Many As One In Seven Cats 7/30/2025

    PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide.

  2. Actio Biosciences Announces U.S. FDA Clearance Of Investigational New Drug Application And Fast Track Designation For ABS-1230, A KCNT1 Inhibitor For The Treatment Of KCNT1-Related Epilepsy 7/30/2025

    Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application and granted Fast Track designation for ABS-1230, an expected first-in-class, orally administered small molecule KCNT1 inhibitor, for the treatment of KCNT1-related epilepsy.

  3. Alpha Cognition Announces Partner China Medical System Has NDA Accepted In China For The Review Of ZUNVEYL (Benzgalantamine) For Alzheimer's Disease 7/29/2025

    Alpha Cognition Inc. (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer’s dementia.

  4. Precision BioSciences Receives FDA Orphan Drug Designation For PBGENE-DMD For The Treatment Of Duchenne Muscular Dystrophy 7/23/2025

    Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

  5. Introducing Latent-X, A Frontier Generative AI Model For Protein Binder Design Accessible Via No-Code Platform For Push-Button Protein Design 7/22/2025

    Today, Latent Labs is launching Latent-X, a frontier AI model for push button protein design, outperforming competing models under identical laboratory conditions.

  6. Lantern Pharma Secures EU Patent Allowance For LP-284, Bolstering Global IP Position For AI-Developed Cancer Therapy 7/21/2025

    Lantern Pharma Inc. a clinical-stage oncology company leveraging its proprietary RADR artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284.

  7. Elix Provides AI Drug Discovery Platform 'Elix Discovery' To Eisai 7/17/2025

    Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix Discovery (https://www.elix-inc.com/platform/), has been adopted by Eisai Co., Ltd. (Headquarters: Tokyo; hereinafter “Eisai”).

  8. Corcept Submits New Drug Application For Relacorilant As A Treatment For Patients With Platinum-Resistant Ovarian Cancer 7/14/2025

    Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer.

  9. Integrated Biosciences Unveils First-Of-Its-Kind Optogenetic Screening Platform For Drug Discovery 7/14/2025

    Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, today announced the publication of a landmark study in Cell, introducing its first-of-a-kind optogenetic screening platform.

  10. TandemAI And Perpetual Medicines Announce Strategic Merger To Expand Physics And AI-Based Drug Discovery Capabilities 7/10/2025

    TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpetual Medicines, which is advancing a computational design-synthesis platform for peptide drug discovery today announced the companies have merged.